| Name | Title | Contact Details |
|---|
NexMed, Inc. (NASDAQ: NEXM), due to its recent acquisition of Bio-Quant, Inc., a revenue-generating specialty contract research organization performing in vitro and in vivo pharmacology services, is now the largest specialty CRO based in San Diego, CA.
Community Medical Services is a CARF–accredited addiction treatment program providing services in the form of outpatient medication-assisted treatment and private one–on–one and group counseling, Intensive Out-Patient therapy (IOP) and Moral Reconation Therapy (MRT) to those seeking help with their substance use disorders. We have a total of 14 clinics throughout the United States. We have seven Arizona locations which cater to Phoenix, Glendale, Mesa, Scottsdale, and Tempe; a clinic in East Tucson, Northwest Tucson, Safford and Casa Grande; four clinics in Montana located in Missoula, Kalispell, Billings and Belgrade, which cater to clients in Bozeman and Helena; a clinic in Wasilla, Alaska catering to the Mat-Su Valley and Anchorage, and two clinics in North Dakota, one located in Minot, catering to clients in Williston and Bismarck and a clinic in Fargo, catering to clients from Fargo/Moorhead, West Fargo, Grand Forks, and Minnesota.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
NUCATS provides scientists with consultative resources and expertise in order to accelerate how quickly transformative scientific discoveries make their way to patients and the community. It is our goal to continually increase the quality, safety, efficiency and speed of innovative clinical and translational research.
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.